Up­dat­ed: No­var­tis ax­es blood can­cer drug af­ter PhI­II flop, cau­tions on obe­si­ty FO­MO

No­var­tis is wind­ing down a blood can­cer pro­gram hit­ting TIM-3, end­ing the pur­suit of a once-promis­ing im­muno-on­col­o­gy tar­get.

The cut comes as No­var­tis con­sol­i­dates around …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER